AU2009309277A1 - Efficient expression of truncated human RNASET2 in E. Coli - Google Patents

Efficient expression of truncated human RNASET2 in E. Coli Download PDF

Info

Publication number
AU2009309277A1
AU2009309277A1 AU2009309277A AU2009309277A AU2009309277A1 AU 2009309277 A1 AU2009309277 A1 AU 2009309277A1 AU 2009309277 A AU2009309277 A AU 2009309277A AU 2009309277 A AU2009309277 A AU 2009309277A AU 2009309277 A1 AU2009309277 A1 AU 2009309277A1
Authority
AU
Australia
Prior art keywords
rnaset2
truncated
human
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009309277A
Other languages
English (en)
Other versions
AU2009309277A8 (en
Inventor
Liron Nuttman
Levava Roiz
Betty Schwartz
Oded Shoseyov
Patricia Smirnoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU2009309277A1 publication Critical patent/AU2009309277A1/en
Publication of AU2009309277A8 publication Critical patent/AU2009309277A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2009309277A 2008-10-30 2009-10-29 Efficient expression of truncated human RNASET2 in E. Coli Abandoned AU2009309277A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19313408P 2008-10-30 2008-10-30
US61/193,134 2008-10-30
PCT/IL2009/001012 WO2010049933A1 (en) 2008-10-30 2009-10-29 Efficient expression of truncated human rnaset2 in e. coli

Publications (2)

Publication Number Publication Date
AU2009309277A1 true AU2009309277A1 (en) 2010-05-06
AU2009309277A8 AU2009309277A8 (en) 2011-05-12

Family

ID=41694413

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009309277A Abandoned AU2009309277A1 (en) 2008-10-30 2009-10-29 Efficient expression of truncated human RNASET2 in E. Coli

Country Status (8)

Country Link
US (1) US20110207667A1 (https=)
EP (1) EP2346993A1 (https=)
JP (1) JP2012507278A (https=)
AU (1) AU2009309277A1 (https=)
CA (1) CA2739705A1 (https=)
EA (1) EA201100610A1 (https=)
WO (1) WO2010049933A1 (https=)
ZA (1) ZA201102615B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508662A (ja) * 2012-02-29 2015-03-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １→３リーディングフレームシフトを減少させるための方法
US11685935B2 (en) * 2013-05-29 2023-06-27 Cellectis Compact scaffold of Cas9 in the type II CRISPR system
WO2015114633A1 (en) 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
US11186872B2 (en) * 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021830A1 (en) * 1999-09-24 2001-03-29 Ambion, Inc. Nuclease inhibitor cocktail
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1805319B1 (en) * 2004-09-29 2014-09-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Recombinant human t2 rnase and uses thereof
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof

Also Published As

Publication number Publication date
AU2009309277A8 (en) 2011-05-12
EP2346993A1 (en) 2011-07-27
EA201100610A1 (ru) 2011-10-31
ZA201102615B (en) 2012-03-28
US20110207667A1 (en) 2011-08-25
JP2012507278A (ja) 2012-03-29
CA2739705A1 (en) 2010-05-06
WO2010049933A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
Campuzano et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes
EP3341396B1 (en) Improved cell-permeable (icp)-socs3 recombinant protein and uses thereof
Mykkänen et al. Characterization of human palladin, a microfilament-associated protein
US8735127B2 (en) Methods of and compositions for inhibiting the proliferation of mammalian cells
KR100506786B1 (ko) 섬유아세포 성장인자-19
KR101838670B1 (ko) 미락 단백질
ES2206448T3 (es) Heregulinas (hrgs), proteinas de union de p185?erb2.
US6723506B2 (en) Method of identifying PAX8-PPAR gamma-nucleic acid molecules
US20110207667A1 (en) Efficient expression of truncated human rnaset2 in e. coli
WO2014046481A1 (ko) 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
ES2355055T3 (es) Composiciones y procedimientos para el tratamiento de tumores.
EP1805319B1 (en) Recombinant human t2 rnase and uses thereof
KR20030074702A (ko) 모듈식 트랜스펙션 시스템
CA2145769A1 (en) Trophic factor having ion channel-inducing activity in neuronal cells
CN101643511B (zh) 抑制端粒酶活性的融合蛋白、其制备及应用
KR101898502B1 (ko) 인슐린-유사 성장 인자 1 수용체 결합 펩티드
KR20010103576A (ko) 종양 치료용 조성물 및 치료 방법
WO2002099104A1 (fr) Polypeptide destabilisant une proteine dans des cellules dans des conditions aerobies et adn codant pour ce polypeptide
Thomson et al. A method for expression and purification of soluble, active Hsp47, a collagen-specific molecular chaperone
WO2015114633A1 (en) Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
KR100448427B1 (ko) 신생 세포 성장을 억제하기 위한 방법 및 조성물
WO2009113965A1 (en) Isthmin derivatives for use in treating angiogenesis
US20060134719A1 (en) Novel serine protease
Graceffa Investigation on Cross-correction of Cystinosis through Genetically Engineered Cells Secreting Cystinosin
CA2599566A1 (en) Insulin-like growth factor binding protein-4 compounds and methods for inhibiting angiogenesis and tumor growth in mammalian cells

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 25, NO 17, PAGE(S) 2088 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., APPLICATION NO. 2009309277, UNDER INID (54) CORRECT THE TITLE TO EFFICIENT EXPRESSION OF TRUNCATED HUMAN RNASET2 IN E. COLI

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application